Metabolomics strategies to discover new biomarkers associated to severe allergic phenotypes
10.5415/apallergy.2019.9.e37
- Author:
Domingo BARBER
1
;
Alma VILLASEÑOR
;
Maria M ESCRIBESE
Author Information
1. IMMA, Instituto de Medicina Molecular Aplicada, Facultad de Medicina, Universidad San Pablo CEU, Madrid, Spain. domingo.barberhernandez@ceu.es
- Publication Type:Review
- Keywords:
Metabolomics;
Biomarkers;
Severe allergic phenotype
- MeSH:
Biomarkers;
Diagnosis;
Disease Progression;
Humans;
Hypersensitivity;
Metabolomics;
Methods;
Phenotype
- From:
Asia Pacific Allergy
2019;9(4):e37-
- CountryRepublic of Korea
- Language:English
-
Abstract:
In the last decades have emerged new technological platforms that allow evaluation of genes, transcripts, proteins, or metabolites of a living being, so-called omics sciences. More importantly, new technics for their integration have provided access to a complete set of information of the current conditions and features of a specific biological sample in a precise moment. Thus, omic sciences are now considered an essential tool for patient stratification in base to their severity, to understand disease progression and to identify new biomarkers. Severe patients, that are out of control, provide an excellent model to understand disease evolution and to identify new intervention and biomarkers strategies. Here we discuss the use of metabolomics to understand severity in allergic diseases in a strategy that opens new insights as well as identify new biological systems relevant for allergy progression. Metabolomics strategies are based in parallel evaluation of different allergy severity models by mean of untargeted analysis that allows the identification of potential biomarkers. Overlapping of different biomarkers in multiple models, provides information of general as well as specific biological systems involved in each model. Later a selected panel of biomarkers will be used in a target method to explore the diagnosis potential to stratify allergic patients.
